Ryan T Hughes1, Mercedes Porosnicu2, Beverly J Levine3, Thomas W Lycan2, Rachel F Shenker4, Bart A Frizzell1, Kathryn M Greven1. 1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA. 2. Depatment of Internal Medicine-Section of Hematology and Oncology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA. 3. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston Salem, North Carolina, USA. 4. Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
INTRODUCTION: Concurrent chemoradiotherapy (CRT) using high-dose cisplatin (HDC) is standard for patients with locally advanced head and neck squamous cell carcinoma (HNSCC); weekly cisplatin (WC) is an alternative. We aim to compare retrospectively the survival and disease control outcomes between these regimens in our institutional experience. METHODS: Patients with stage III-IV HNSCC treated with definitive or postoperative CRT between 2012 and 2018 were identified. Patients were stratified by intent-to-treat CRT. Overall survival (OS) and disease-free survival (DFS) were generated and multivariable Cox models were performed. RESULTS: 193 patients were treated with concurrent HDC (n = 69), WC at 40 mg/m2 (WC40, n = 88) or WC at <40 mg/m2 (WC<40, n = 36). Treatment intent was definitive in 74% and adjuvant in 26%. Baseline differences included age, performance status and HPV status. Cumulative cisplatin dose ≥200 mg/m2 was achieved in 89% (HDC), 86% (WC40) and 25% (WC<40, P < 0.0001). For HDC, WC40 and WC<40, 2-year OS rates were 87%, 77%, 60% and 2-year DFS rates were 75%, 68% and 52%, respectively. Multivariable analysis revealed gender, performance status, primary site, T/N stage and chemotherapy as predictive of OS. Primary site, T/N stage and chemotherapy regimen were associated with DFS. Compared with HDC, no differences in locoregional control (LRC) or distant metastasis were observed between groups. CONCLUSION: Concurrent HDC is associated with increased total cisplatin intensity, OS and DFS compared with weekly cisplatin regimens. LRC was not associated with chemotherapy regimen. HDC remains the standard of care; WC40 is a reasonable alternative that does not appear to sacrifice LRC.
INTRODUCTION: Concurrent chemoradiotherapy (CRT) using high-dose cisplatin (HDC) is standard for patients with locally advanced head and neck squamous cell carcinoma (HNSCC); weekly cisplatin (WC) is an alternative. We aim to compare retrospectively the survival and disease control outcomes between these regimens in our institutional experience. METHODS: Patients with stage III-IV HNSCC treated with definitive or postoperative CRT between 2012 and 2018 were identified. Patients were stratified by intent-to-treat CRT. Overall survival (OS) and disease-free survival (DFS) were generated and multivariable Cox models were performed. RESULTS: 193 patients were treated with concurrent HDC (n = 69), WC at 40 mg/m2 (WC40, n = 88) or WC at <40 mg/m2 (WC<40, n = 36). Treatment intent was definitive in 74% and adjuvant in 26%. Baseline differences included age, performance status and HPV status. Cumulative cisplatin dose ≥200 mg/m2 was achieved in 89% (HDC), 86% (WC40) and 25% (WC<40, P < 0.0001). For HDC, WC40 and WC<40, 2-year OS rates were 87%, 77%, 60% and 2-year DFS rates were 75%, 68% and 52%, respectively. Multivariable analysis revealed gender, performance status, primary site, T/N stage and chemotherapy as predictive of OS. Primary site, T/N stage and chemotherapy regimen were associated with DFS. Compared with HDC, no differences in locoregional control (LRC) or distant metastasis were observed between groups. CONCLUSION: Concurrent HDC is associated with increased total cisplatin intensity, OS and DFS compared with weekly cisplatin regimens. LRC was not associated with chemotherapy regimen. HDC remains the standard of care; WC40 is a reasonable alternative that does not appear to sacrifice LRC.
Authors: Jean Bourhis; Christian Sire; Pierre Graff; Vincent Grégoire; Philippe Maingon; Gilles Calais; Bernard Gery; Laurent Martin; Marc Alfonsi; Patrick Desprez; Thierry Pignon; Etienne Bardet; Michel Rives; Lionel Geoffrois; Nicolas Daly-Schveitzer; Sok Sen; Claude Tuchais; Olivier Dupuis; Stéphane Guerif; Michel Lapeyre; Véronique Favrel; Marc Hamoir; Antoine Lusinchi; Stéphane Temam; Antonella Pinna; Yun Gan Tao; Pierre Blanchard; Anne Aupérin Journal: Lancet Oncol Date: 2012-01-18 Impact factor: 41.316
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jay S Cooper; Qiang Zhang; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Robert Lustig; John F Ensley; Wade Thorstad; Christopher J Schultz; Sue S Yom; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-30 Impact factor: 7.038
Authors: Harry Quon; Traci Leong; Robert Haselow; Bruce Leipzig; Jay Cooper; Arlene Forastiere Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-01 Impact factor: 7.038
Authors: Irina Y Dobrosotskaya; Emily Bellile; Matthew E Spector; Bhavna Kumar; Felix Feng; Avraham Eisbruch; Gregory T Wolf; Mark E P Prince; Jeffrey S Moyer; Theodoros Teknos; Douglas B Chepeha; Heather M Walline; Jonathan B McHugh; Kitrina G Cordell; P Daniel Ward; Serena Byrd; Jessica H Maxwell; Susan Urba; Carol R Bradford; Thomas E Carey; Francis P Worden Journal: Head Neck Date: 2013-07-02 Impact factor: 3.147
Authors: Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Zachary Patel; Jennifer A Schroeder; Paul M Bunch; Joni K Evans; Cole R Steber; Adam G Johnson; Joshua C Farris; Ryan T Hughes Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-10-01 Impact factor: 8.961